Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon Strikes Biomarker Discovery Partnership With Cleveland Clinic

NEW YORK — Metabolon said on Thursday that it has signed an agreement to support drug development and related research at the Cleveland Clinic.

Under the terms of the deal, Metabolon will apply its Precision Metabolomics liquid chromatography-mass spectrometry global metabolomics platform — which identifies pharmacodynamic, efficacy, and response biomarkers and tracks changes in biological pathways — to large-scale population health programs underway at the Cleveland Clinic.

Metabolon said that it aims to analyze a range of biological samples to discover metabolomic biomarkers that can help inform these research efforts.

Additional terms of the deal were not disclosed.

"Metabolomics is an essential element of the multi-omics approach that is being employed by Cleveland Clinic to transform healthcare by understanding disease progression and therapeutic response more deeply," Metabolon Scientific Director Greg Michelotti said in a statement.

In August, Morrisville, North Carolina-based Metabolon inked a deal to use its Precision Metabolomics platform to advance drug-development work at Germany's Merck KGaA.